[go: up one dir, main page]

WO1999000145A9 - Modulation antigenique de particules virales - Google Patents

Modulation antigenique de particules virales Download PDF

Info

Publication number
WO1999000145A9
WO1999000145A9 PCT/US1998/013198 US9813198W WO9900145A9 WO 1999000145 A9 WO1999000145 A9 WO 1999000145A9 US 9813198 W US9813198 W US 9813198W WO 9900145 A9 WO9900145 A9 WO 9900145A9
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
immunogenic
red blood
mpeg
Prior art date
Application number
PCT/US1998/013198
Other languages
English (en)
Other versions
WO1999000145A1 (fr
Inventor
Mark D Scott
John W Eaton
Original Assignee
Albany Medical College
Mark D Scott
John W Eaton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Medical College, Mark D Scott, John W Eaton filed Critical Albany Medical College
Priority to AU79878/98A priority Critical patent/AU7987898A/en
Publication of WO1999000145A1 publication Critical patent/WO1999000145A1/fr
Publication of WO1999000145A9 publication Critical patent/WO1999000145A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à une composition cellulaire non immunogène qui comprend: une cellule, notamment une particule virale ou un virus, possédant une surface cellulaire et portant sur cette surface des déterminants antigéniques; éventuellement, une molécule de liaison liée par covalence à la surface cellulaire; et un composé non immunogène (tel que du polyéthylèneglycol ou un dérivé de celui-ci) lié par covalence à la molécule de liaison ou directement fixé à la cellule. Dans un mode de réalisation, la molécule de liaison est directement liée par covalence au déterminant antigénique sur la surface cellulaire. Dans un autre mode de réalisation, la molécule de liaison est liée par covalence à un site non antigénique sur la surface cellulaire et, en même temps, camoufle le déterminant antigénique sur ladite surface cellulaire. L'invention concerne également divers usages de la cellule virale non immunogène obtenue de cette manière, notamment une méthode permettant de lutter contre la phagocytose d'une cellule virale, une méthode permettant d'atténuer les effets indésirables d'une transfusion, une méthode permettant de lutter contre le rejet d'une cellule virale, d'un tissu ou d'un organe transplanté et une méthode permettant de lutter contre l'agrégation de cellules induite par des anticorps.
PCT/US1998/013198 1997-06-26 1998-06-25 Modulation antigenique de particules virales WO1999000145A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79878/98A AU7987898A (en) 1997-06-26 1998-06-25 Antigenic modulation of viral particules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88344797A 1997-06-26 1997-06-26
US08/883,447 1997-06-26

Publications (2)

Publication Number Publication Date
WO1999000145A1 WO1999000145A1 (fr) 1999-01-07
WO1999000145A9 true WO1999000145A9 (fr) 1999-04-15

Family

ID=25382598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013198 WO1999000145A1 (fr) 1997-06-26 1998-06-25 Modulation antigenique de particules virales

Country Status (2)

Country Link
AU (1) AU7987898A (fr)
WO (1) WO1999000145A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615637C (fr) * 2006-12-22 2014-12-02 Canadian Blood Services Prevention de la formation de biofilms au moyen de produits sanguins modifies avec du peg ou certains de ses derives
US7964339B2 (en) * 2007-02-09 2011-06-21 Canadian Blood Services Cold storage of modified platelets
US8067151B2 (en) 2007-02-09 2011-11-29 Canadian Blood Services Cold storage of pegylated platelets at about or below 0° C.
EP2163261A1 (fr) * 2008-07-14 2010-03-17 Canadian Blood Services Stockage à basse température de plaquettes modifiées au PEG
US10434070B2 (en) 2015-01-02 2019-10-08 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to enable blood transfusion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
EP0831922A2 (fr) * 1995-06-08 1998-04-01 Therexsys Limited Compositions pharmaceutiques ameliorees utilisees pour la therapie genique
AU1555297A (en) * 1996-02-01 1997-08-22 Biomedical Frontiers, Inc. Antigenic modulation of cells
EP0921817B1 (fr) * 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Procede de p.e.g.ylation

Also Published As

Publication number Publication date
WO1999000145A1 (fr) 1999-01-07
AU7987898A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
US5908624A (en) Antigenic modulation of cells
EP0901521B1 (fr) Modulation antigenique de cellules
Scott et al. Cellular camouflage: fooling the immune system with polymers
Scott et al. Beyond the red cell: pegylation of other blood cells and tissues
US6139836A (en) Method of encapsulating biologically active agents within erythrocytes, and apparatus therefor
US5767093A (en) Methods for attenuating antibody-mediated xenograft rejection in human recipients
Scott et al. Camouflaged blood cells: low-technology bioengineering for transfusion medicine?
Kyluik-Price et al. Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly (ethylene glycol) and polyethyloxazoline
Ravilla et al. Erythrocytes as carrier for drugs, enzymes and peptides
Le et al. Immunogenicity of murine mPEG-red blood cells and the risk of anti-PEG antibodies in human blood donors
US20030207247A1 (en) Preparation of red blood cells having reduced immunogenicity
WO1999000145A9 (fr) Modulation antigenique de particules virales
US6956025B2 (en) Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
US8007784B1 (en) Antigenic modulation of cells
WO2004050897A2 (fr) Procedes de preparation de globules rouges a masquage d'antigene et hemolyse reduite au moyen de serums
US5885570A (en) Induction of tolerance with modified immunogens
US5977079A (en) Compositions for attenuating antibody- mediated xenograft rejection in human recipients
JP3085963B2 (ja) 人工血液
Scott et al. The other blood substitute: antigenically inert erythrocytes
Bellad et al. Resealed erythrocytes based drug delivery system
Shenoi Sugar-based systems
Muzykantov et al. Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes
US20020141976A1 (en) Red blood cells covalently bound with polymers
US12042545B2 (en) Encapsulated extracellular vesicles
Nacharaju et al. Generation of universal red blood cells: an evaluation of various approaches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: JP

Ref document number: 1999505711

Format of ref document f/p: F

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA